Bright Minds Biosciences Inc. (CSE:DRUG)
Canada flag Canada · Delayed Price · Currency is CAD
109.94
+7.23 (7.04%)
Mar 9, 2026, 3:38 PM EST

Bright Minds Biosciences Cash Flow Statement

Millions CAD. Fiscal year is Oct - Sep.
Fiscal Year
TTM FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 2020 - 2019
Period Ending
Dec '25 Sep '25 Sep '24 Sep '23 Sep '22 Sep '21 2020 - 2019
Net Income
-19.84-12.23-2.8-7.37-14.96-8.65
Upgrade
Depreciation & Amortization
0.080.080.070.070.01-
Upgrade
Asset Writedown & Restructuring Costs
----0-
Upgrade
Stock-Based Compensation
4.293.180.841.150.90.88
Upgrade
Other Operating Activities
2.79-0.28-00.07-0.260.14
Upgrade
Change in Accounts Payable
1.031.690.24-1.20.770.51
Upgrade
Change in Other Net Operating Assets
-1.35-1.13-0.20.26-0.04-0.2
Upgrade
Operating Cash Flow
-13.01-8.69-1.85-7.02-13.59-7.32
Upgrade
Long-Term Debt Repaid
--0.1-0.09-0.09-0.01-
Upgrade
Net Debt Issued (Repaid)
-0.1-0.1-0.09-0.09-0.01-
Upgrade
Issuance of Common Stock
50.4286.030.91.47627.84
Upgrade
Other Financing Activities
-3.4-0.36-0.8-0.8-1.79
Upgrade
Financing Cash Flow
46.9285.570.812.195.226.06
Upgrade
Foreign Exchange Rate Adjustments
-2.750.310.01-0.050.260.22
Upgrade
Net Cash Flow
31.1577.19-1.03-4.88-8.1318.96
Upgrade
Levered Free Cash Flow
-7.7-4.6-0.69-4.22-7.58-3.85
Upgrade
Unlevered Free Cash Flow
-7.67-4.58-0.69-4.22-7.58-3.85
Upgrade
Change in Working Capital
-0.320.550.04-0.940.720.31
Upgrade
Source: S&P Capital IQ. Standard template. Financial Sources.